vs
Absci Corp（ABSI）与MAXCYTE, INC.（MXCT）财务数据对比。点击上方公司名可切换其他公司
MAXCYTE, INC.的季度营收约是Absci Corp的7.4倍（$4.8M vs $650.0K）。MAXCYTE, INC.净利率更高（-200.5% vs -4548.0%，领先4347.5%）。Absci Corp同比增速更快（-2.3% vs -20.9%）。MAXCYTE, INC.自由现金流更多（$-2.9M vs $-29.3M）。过去两年MAXCYTE, INC.的营收复合增速更高（-7.4% vs -14.9%）
Absci Corp是一家结合合成生物学与人工智能技术的生物技术企业，为全球制药及生物制药合作伙伴提供集成式蛋白质工程解决方案，加速抗体、治疗性蛋白等新型生物候选药物的研发，助力满足未被覆盖的临床医疗需求。
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
ABSI vs MXCT — 直观对比
营收规模更大
MXCT
是对方的7.4倍
$650.0K
营收增速更快
ABSI
高出18.7%
-20.9%
净利率更高
MXCT
高出4347.5%
-4548.0%
自由现金流更多
MXCT
多$26.4M
$-29.3M
两年增速更快
MXCT
近两年复合增速
-14.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $650.0K | $4.8M |
| 净利润 | $-29.6M | $-9.6M |
| 毛利率 | — | — |
| 营业利润率 | -4775.5% | -234.5% |
| 净利率 | -4548.0% | -200.5% |
| 营收同比 | -2.3% | -20.9% |
| 净利润同比 | -2.0% | 9.4% |
| 每股收益（稀释后） | $-0.19 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABSIMXCT
| Q4 25 | $650.0K | $4.8M | ||
| Q3 25 | $378.0K | $4.6M | ||
| Q2 25 | $593.0K | $5.8M | ||
| Q1 25 | $1.2M | $5.7M | ||
| Q4 24 | $665.0K | $6.1M | ||
| Q3 24 | $1.7M | $5.6M | ||
| Q2 24 | $1.3M | $5.0M | ||
| Q1 24 | $898.0K | $5.6M |
净利润ABSIMXCT
| Q4 25 | $-29.6M | $-9.6M | ||
| Q3 25 | $-28.7M | $-12.4M | ||
| Q2 25 | $-30.6M | $-12.4M | ||
| Q1 25 | $-26.3M | $-10.3M | ||
| Q4 24 | $-29.0M | $-10.6M | ||
| Q3 24 | $-27.4M | $-11.6M | ||
| Q2 24 | $-24.8M | $-9.4M | ||
| Q1 24 | $-22.0M | $-9.5M |
营业利润率ABSIMXCT
| Q4 25 | -4775.5% | -234.5% | ||
| Q3 25 | -7977.2% | -307.4% | ||
| Q2 25 | -5293.9% | -244.3% | ||
| Q1 25 | -2351.9% | -214.1% | ||
| Q4 24 | -4477.3% | -213.1% | ||
| Q3 24 | -1698.7% | -250.4% | ||
| Q2 24 | -2104.0% | -241.0% | ||
| Q1 24 | -2616.7% | -219.8% |
净利率ABSIMXCT
| Q4 25 | -4548.0% | -200.5% | ||
| Q3 25 | -7594.2% | -269.7% | ||
| Q2 25 | -5155.0% | -212.2% | ||
| Q1 25 | -2234.6% | -178.7% | ||
| Q4 24 | -4358.3% | -175.0% | ||
| Q3 24 | -1610.7% | -205.9% | ||
| Q2 24 | -1948.8% | -188.8% | ||
| Q1 24 | -2447.1% | -170.6% |
每股收益（稀释后）ABSIMXCT
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $-0.20 | $-0.12 | ||
| Q2 25 | $-0.24 | $-0.12 | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.24 | $-0.11 | ||
| Q2 24 | $-0.22 | $-0.09 | ||
| Q1 24 | $-0.22 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $103.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $189.4M | $171.5M |
| 总资产 | $216.3M | $202.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABSIMXCT
| Q4 25 | $144.3M | $103.0M | ||
| Q3 25 | $152.5M | $105.7M | ||
| Q2 25 | $38.0M | $126.6M | ||
| Q1 25 | $47.0M | $138.3M | ||
| Q4 24 | $112.4M | $154.5M | ||
| Q3 24 | $38.2M | $153.8M | ||
| Q2 24 | $42.9M | $157.3M | ||
| Q1 24 | $58.8M | $157.5M |
总债务ABSIMXCT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABSIMXCT
| Q4 25 | $189.4M | $171.5M | ||
| Q3 25 | $210.3M | $180.3M | ||
| Q2 25 | $173.4M | $190.7M | ||
| Q1 25 | $198.8M | $199.4M | ||
| Q4 24 | $179.1M | $206.3M | ||
| Q3 24 | $201.3M | $213.3M | ||
| Q2 24 | $221.5M | $221.3M | ||
| Q1 24 | $240.1M | $226.4M |
总资产ABSIMXCT
| Q4 25 | $216.3M | $202.5M | ||
| Q3 25 | $245.0M | $213.5M | ||
| Q2 25 | $209.9M | $219.8M | ||
| Q1 25 | $232.4M | $230.0M | ||
| Q4 24 | $213.6M | $239.5M | ||
| Q3 24 | $235.2M | $248.6M | ||
| Q2 24 | $255.5M | $251.5M | ||
| Q1 24 | $274.9M | $257.9M |
负债/权益比ABSIMXCT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.2M | $-2.7M |
| 自由现金流经营现金流 - 资本支出 | $-29.3M | $-2.9M |
| 自由现金流率自由现金流/营收 | -4505.4% | -61.0% |
| 资本支出强度资本支出/营收 | 15.8% | 4.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-94.2M | $-36.2M |
8季度趋势，按日历期对齐
经营现金流ABSIMXCT
| Q4 25 | $-29.2M | $-2.7M | ||
| Q3 25 | $-25.0M | $-7.5M | ||
| Q2 25 | $-16.9M | $-9.9M | ||
| Q1 25 | $-21.8M | $-14.4M | ||
| Q4 24 | $-17.0M | $-7.8M | ||
| Q3 24 | $-20.7M | $-4.4M | ||
| Q2 24 | $-16.8M | $-4.8M | ||
| Q1 24 | $-17.9M | $-10.6M |
自由现金流ABSIMXCT
| Q4 25 | $-29.3M | $-2.9M | ||
| Q3 25 | $-26.0M | $-7.8M | ||
| Q2 25 | $-17.1M | $-10.4M | ||
| Q1 25 | $-21.9M | $-15.1M | ||
| Q4 24 | $-17.0M | $-8.0M | ||
| Q3 24 | $-20.8M | $-4.8M | ||
| Q2 24 | $-17.2M | $-5.1M | ||
| Q1 24 | — | $-11.4M |
自由现金流率ABSIMXCT
| Q4 25 | -4505.4% | -61.0% | ||
| Q3 25 | -6876.5% | -168.5% | ||
| Q2 25 | -2883.0% | -179.2% | ||
| Q1 25 | -1854.5% | -262.3% | ||
| Q4 24 | -2554.4% | -131.6% | ||
| Q3 24 | -1221.6% | -85.5% | ||
| Q2 24 | -1352.4% | -103.3% | ||
| Q1 24 | — | -203.6% |
资本支出强度ABSIMXCT
| Q4 25 | 15.8% | 4.8% | ||
| Q3 25 | 254.5% | 6.5% | ||
| Q2 25 | 37.6% | 10.0% | ||
| Q1 25 | 2.1% | 11.4% | ||
| Q4 24 | 3.5% | 2.4% | ||
| Q3 24 | 2.8% | 7.2% | ||
| Q2 24 | 26.2% | 5.9% | ||
| Q1 24 | 0.0% | 14.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
